Improving skeletal muscle in Veterans with HIV
Official title: A Randomized Trial to Optimize Skeletal Muscle While Reducing Adiposity in Veterans With HIV
Run by VA Office of Research and Development · NCT06845046 · Data updated 2026-11-12
This will test whether switching saturated fats to unsaturated fats, giving L‑carnitine and omega‑3 supplements, and adding targeted resistance exercise can reduce fat in muscle and improve muscle health in Veterans with HIV and obesity.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 80 Years |
| Sex | Men only |
| Enrollment | 70 (estimated) |
| Sponsor | VA Office of Research and Development Federal |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | July 15, 2025 |
| Main results expected | March 30, 2029 |
| Study ends | March 30, 2029 |
| Registry record updated | June 26, 2026 |
| Trial ID | NCT06845046 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Veterans living with HIV who are on an integrase strand transfer inhibitor with HIV‑1 RNA <50 copies/mL, aged 20 or older, and with a BMI of 28–50 kg/m2.
✕Probably not a fit
People with diagnosed diabetes, unstable recent weight change, diagnosed mitochondrial disorders, stage 3+ kidney disease, or who cannot do the exercise testing/training are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial enrolls Veterans living with HIV who are virally suppressed on integrase‑based ART and have obesity, and delivers a multipronged intervention combining dietary fat replacement (less saturated, more unsaturated fats), L‑carnitine plus omega‑3 supplementation, and targeted resistance exercise training compared with a control diet. Outcomes include changes in muscle fat infiltration measured by CT (muscle density), mitochondrial oxidative capacity, inflammation markers, muscle glucose handling, and physical function. Participants with contraindications such as diabetes, unstable weight, significant kidney disease, or MRI/CPET incompatibility are excluded. The aim is to mobilize and metabolize ectopic muscle fat while preserving or increasing muscle mass to reduce frailty and cardiometabolic risk in this population.
Why it matters
Potential benefit: If successful, the approach could reduce harmful fat in and around muscle, improve strength and physical function, and lower cardiometabolic risk for Veterans with HIV and obesity.
How similar studies have gone: Individual components such as omega‑3s, L‑carnitine, dietary fat modification, and resistance training have shown metabolic or muscle benefits in other populations, but combining them specifically to target myosteatosis in Veterans with treated HIV is a novel, largely untested approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Veteran * HIV+ * antiretroviral therapy = integrase strand transfer inhibitor for at least 3 months * HIV-1 RNA \<50 copies/ml * age = 20 yrs * BMI 28-50 kg/m2 Exclusion Criteria: * unstable body weight (gain or loss \> 5% over past 3 months) * diagnosed mitochondrial disorder * diagnosed type 1 or type 2 diabetes * use of metformin or other anti-diabetic agents for pre-diabetes * hemoglobin A1c of \>6.5% at screening visit * inflammatory conditions or chronic corticosteroid use * stage 3 or greater kidney disease * dietary or herbal supplements known to affect body weight, muscle mass, or immune function * MRI incompatibility * inability to perform physical function tests due to anatomical limitations * contradictions to CPET such as exercise-induced ischemia or supplemental oxygen
Where it's running
-
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
Nashville, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Heidi J Silver, PhD — Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
- Study coordinator: Heidi J Silver, PhD
- Email: heidi.j.silver@vumc.org
- Phone: (615) 875-9355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.